Releases

Date Title and Summary Additional Formats
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 20/2018 To: NASDAQ Copenhagen A/S                                                Copenhagen, Denmark, 06 December 2018   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018
Company Release no. 19/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 14 November 2018 Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights Product revenue for first nine months of 2018 was USD 27.8 million, an increase of 101% compared to the same
View HTML
Toggle Summary Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S
Company Release no. 18/2018 To: NASDAQ Copenhagen A/S                                                  Copenhagen, Denmark, 31 October 2018 Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S   Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Ira
View HTML
Toggle Summary Veloxis to Present at Jefferies 2018 London Healthcare Conference
Investor News no. 03/2018 To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 10 October 2018 Veloxis to Present at the Jefferies 2018 London Healthcare Conference Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that CEO Craig Collard will present
View HTML
Toggle Summary Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals A/S
Company Announcement no. 17/2018 To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 24 September 2018 Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Morten
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 August 2018
Company Release no. 16/2018 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 31 August 2018 Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 August 2018 Veloxis Pharmaceuticals A/S announces, in accordance with
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 15/2018 To: NASDAQ Copenhagen A/S                                                Copenhagen, Denmark, 23 August 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018
Veloxis Upgrades 2018 Outlook Based on Strong Performance Copenhagen, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Highlights Veloxis upgrades 2018 Outlook based on strong performance.   Product revenue for first half of 2018 was USD 17.2 million, an increase of 117% compared to the same period last year.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 13/2018 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 13 July 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
View HTML
Toggle Summary Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation
Veloxis Pharmaceuticals A/S is pleased to announce an ongoing partnership with the American Society of Transplant Surgeons (ASTS) to support the fellowship training of a transplant surgeon with the ASTS-Veloxis Fellowship in Transplantation. The award provides two years of financial support.
View HTML
Toggle Summary Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Company Release no. 12/2018 To:  Nasdaq Copenhagen A/S  Copenhagen, Denmark, 16 May 2018   Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018   Correction: In the company release titled "Veloxis Pharmaceuticals Announces Financial Results for the
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
  Company Release no. 12/2018 To:  Nasdaq Copenhagen A/S  Copenhagen, Denmark, 14 May 2018   Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the First Three Months of 2018.  This
View HTML
Toggle Summary FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Company Release no. 11/2018 To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 19 April 2018    FDA Accepts Veloxis's Supplemental New Drug Application for the  De Novo  Indication for ENVARSUS XR ®     Veloxis Pharmaceuticals A/S announced today that the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 10/2018 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 17 April 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program   Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018
Company Release no. 09/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 April 2018   Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018   Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today, all proposals from the Board of Directors were
View HTML
Toggle Summary Veloxis Appoints Morten Marott as Chief Financial Officer
Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018   Veloxis Appoints Morten Marott as Chief Financial Officer   Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten Marott is joining the company as its new Chief Financial Officer.  Mr.
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2018
Company Release no. 07/2018    To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 31 March 2018    Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2018   Veloxis Pharmaceuticals A/S announces, in accordance with
View HTML
Toggle Summary Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Investor News no. 01/2018   To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 28 March 2018   Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®   Veloxis
View HTML
Toggle Summary Notice to Convene Annual General Meeting 2018
 Company Announcement no. 05/2018   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 22 March 2018   Notice to Convene Annual General Meeting 2018   The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 04/2018   To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 16 March 2018    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®
Veloxis Pharmaceuticals A/S announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant
View HTML
Toggle Summary Veloxis Pharmaceuticals Releases Annual Report for 2017
Company Release no. 2/2018   To: NASDAQ Copenhagen A/S                                          Copenhagen, Denmark, 27 February 2018    Veloxis Pharmaceuticals Releases Annual Report for 2017     Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Annual Report for the financial year 2017.
View HTML
Toggle Summary Veloxis Secures USD 60M in Debt Financing
Company Release no. 01/2018     To: NASDAQ Copenhagen A/S                                                        14 February 2018   Veloxis Secures USD 60M in Debt Financing   Cary, NC, February 14, 2018 -- Veloxis Pharmaceuticals A/S (OMX:VELO), a specialty pharmaceutical company committed to
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017
Company Release no. 27/2017   To: NASDAQ Copenhagen A/S                                        Copenhagen, Denmark, 31 December 2017   Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017   Veloxis Pharmaceuticals A/S announces, in accordance with
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Calendar for 2018
Company Release no. 26/2017   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 29 December 2017                                     Veloxis Pharmaceuticals Announces Financial Calendar for 2018   Veloxis Pharmaceuticals A/S today announced its financial calendar for
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 25/2017   To: NASDAQ Copenhagen A/S                            Copenhagen, Denmark, 22 December 2017       Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program     Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and grant
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 24/2017   To: NASDAQ Copenhagen A/S                                  Copenhagen, Denmark, 01 December 2017    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017
Highlights Record product revenue of tUSD 5,924 achieved in Q3 2017. Revenue reached tUSD 22,092 in the first nine months of 2017 representing an increase of 301% compared to the same period last year. U.S. revenue increased 173% to tUSD 10,943 EU revenue increased 89% to tUSD 2,839 RoW upfront
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 22/2017   To: NASDAQ Copenhagen A/S                    Copenhagen, Denmark, 31 October 2017       Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program   Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and grant warrants to
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 September 2017
Company Release no. 21/2017     To: NASDAQ Copenhagen A/S                    Copenhagen, Denmark, 30 September 2017       Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 September 2017   Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of
View HTML
Toggle Summary Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals A/S
Company Release no. 20/2017   To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 20 September 2017   Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan
View HTML
Toggle Summary Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer
Company Release no. 19/2017     To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 13 September 2017     Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer   Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Announcement no. 18 /2017   To: NASDAQ Copenhagen A/S                                      Copenhagen, Denmark, 12 September 2017    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017
  Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017   Highlights Revenue reached tUSD 16,168 in the first half of 2017 representing an increase of 394% compared to the same period last year.                         U.S.
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017
Company Release no. 16/2017     To: NASDAQ Copenhagen A/S                        Copenhagen, Denmark, 3 July 2017     Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017     Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 15/2017   To: NASDAQ Copenhagen A/S                                                Copenhagen, Denmark, 21 June 2017    Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program  Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 14/2017   To: NASDAQ Copenhagen A/S                                               Copenhagen, Denmark, 15 June 2017    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China
Company Release no. 13/2017     To: NASDAQ Copenhagen A/S                                      Copenhagen, Denmark, 06 June 2017   Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China Veloxis Pharmaceuticals A/S today announced that
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada
Investor News no. 04/2017   To: NASDAQ Copenhagen A/S                            Copenhagen, Denmark, 05 June 2017   Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR ® in Canada   COPENHAGAN, DENMARK & DUBLIN,
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017
Highlights It is now estimated that over 6,000 patients in the US and Europe are being treated with Envarsus XR.   In the US, prescription growth of Envarsus in the first quarter of 2017 grew 19% vs. the fourth quarter of 2016, in contrast to the -2% decline in total tacrolimus market prescriptions
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017
Company Release no. 11/2017   To: NASDAQ Copenhagen A/S                                               Copenhagen, Denmark, 30 April 2017   Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017   Veloxis Pharmaceuticals A/S announces, in accordance with
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2017
Company Release no. 10/2017   To: NASDAQ Copenhagen A/S                                                  Copenhagen, Denmark, 7 April 2017    Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2017   Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today,
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 09/2017     To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 04 April 2017    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2017
Company Release no. 08/2017   To: NASDAQ Copenhagen A/S                    Copenhagen, Denmark, 31 March 2017   Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2017 Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the Danish
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Announces Agreement for Taiba Healthcare to Commercialize Envarsus XR in the Middle East and North Africa Region
Investor News no. 03/2017     To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 31 March 2017   Veloxis Pharmaceuticals A/S Announces Agreement for Taiba Healthcare to Commercialize Envarsus XR in the Middle East and North Africa Region Veloxis Pharmaceuticals A/S
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 07/2017     To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 28 March 2017     Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 06/2017   To: NASDAQ Copenhagen A/S                                 Copenhagen, Denmark, 20 March 2017     Veloxis Increases Share Capital in Connection with Exercise of Warrants      Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Indkaldelse til ordinær generalforsamling
Selskabsmeddelelse nr. 05/2017   Til: NASDAQ OMX Copenhagen A/S                                 København, 16 marts 2017   Indkaldelse til ordinær generalforsamling Bestyrelsen for Veloxis Pharmaceuticals A/S, CVR-nr. 26 52 77 67 ("Selskabet"), indkalder hermed til Selskabets ordinære
View HTML
Toggle Summary Notice to Convene Annual General Meeting 2017
Company Release no. 05/2017   To: NASDAQ Copenhagen A/S                                            Copenhagen, Denmark, 16 March, 2017   Notice to Convene Annual General Meeting 2017 The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 04/2017       To: NASDAQ Copenhagen A/S                     Copenhagen, Denmark, 01 March 2017   Veloxis Pharmaceuticals A/S Grants Warrants Under Existing  Warrant Program   Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to grant warrants to eleven key
View HTML